Medimmune Limited

Glaxo Group Limited

Iain Patrick Chessell

Emmanuel Hubert Demont

David C Lowe

Darren Schofield

Matthew Alexander Sleeman

Mythily Vimal

Robert James Gleave

Daryl Simon Walter

Jonathan P Hatcher

David George Hubert Livermore

David John Davies

Pamela Joan Theobald

Paul John Beswick

Jonathan Hatcher

David Lowe

Laura Jane Chambers

This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNFα antagonist. The NGF antagonist and the TNFα antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNFα antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNFα antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNFα antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNFα antagonist administered alone.

Compounds and methods for treating pain

This disclosure provides compositions and methods for controlling pain. In particular the disclosure provides a method for controlling pain comprising co-administration of an NGF antagonist and a TNF&#x3b1; antagonist. The NGF antagonist and the TNF&#x3b1; antagonist can be separate molecules or part of a multifunctional polypeptide, e.g., a multispecific binding molecule that comprises an NGF antagonist domain and a TNF&#x3b1; antagonist domain. This disclosure also provides multifunctional polypeptides, e.g., multispecific binding molecules, comprising an NGF antagonist domain, and a TNF&#x3b1; antagonist domain. The method provides improved pain control. Administration of an NGF antagonist and a TNF&#x3b1; antagonist as provided herein can control pain in the subject more effectively than an equivalent amount of the NGF antagonist or the TNF&#x3b1; antagonist administered alone.

Growing community of inventors

Essex, United Kingdom

Iain Patrick Chessell